drugset / Trial / NCT00044135

A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.

NCT00044135

Phase 2 Unknown 30 enrolled Triangle Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the safety and effectiveness of 12 weeks of treatment with clevudine, at one of three doses, in patients chronically infected with hepatitis B virus.

Timeline

Start
2002-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Clevudine Small molecule 10 mg
Subject Clevudine Small molecule 30 mg
Subject Clevudine Small molecule 50 mg